Retatrutide, a experimental dual stimulator of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) receptor , is demonstrating promising outcomes in early clinical studies. Ongoing https://bookmarkmargin.com/story21354128/retatrutide-emerging-research-and-potential-medical-roles